Connect Sign In
Latest news
Tracy I. George, MD, ARUP Laboratories’ chief scientific officer and president of the Innovation Business Unit, detailed ARUP’s commitment to cutting-edge diagnostic research during a Rare Disease Day event hosted at Recursion on February 27. The podium featured a zebra, the mascot of people with rare diseases.
ARUP CEO Andy Theurer, Chief Scientific Officer Tracy George, and BioHive leaders watch a video featuring George after ARUP received the Best of BioHive Community Impact Award on Thursday.
The partnership combines Tasso’s clinical grade blood collection solutions, such as the Tasso+ device pictured above, with ARUP’s gold standard testing capabilities to streamline and accelerate decentralized clinical research.
ARUP Laboratories and Augurex Life Sciences Corp. are partnering to incorporate a 14-3-3η test that will aid in the early detection and management of rheumatoid arthritis.
The Tasso+ self-collection device can be shipped directly to patients, facilitating remote collection of whole blood samples and eliminating the need for lab visits.
Tracy George, MD, ARUP chief scientific officer and president of the Innovation Business Unit, accepted an Innovation Award from Utah Business magazine.
The research grant is named in honor of retired ARUP CEO Sherrie Perkins, MD, PhD, whose leadership laid the groundwork for ARUP’s increased focus on innovation.
The AAV5 DetectCDx™ Kit received its Conformitée Européene (CE) mark in January 2022, and testing is being performed by a Medicover facility in Germany.
AAV5 DetectCDx™ detects the presence of anti-AAV5 antibodies to aid in the selection of patients eligible for the treatment ROCTAVIAN™.
Founding members of the new Institute for Research and Innovation in Diagnostic and Precision MedicineTM gather. In the back row, from left to right, are David P. Ng, MD; Hunter Best, PhD, FACMG; Tracy George, MD; Leo Lin, MD, PhD; and Brendan O’Fallon. In the front row, from left to right, are Salika M. Shakir, PhD, D(ABMM); Robert S. Ohgami, MD, PhD, FCAP; Benjamin Bradley, MD, PhD; and Erica Clyde. Not pictured: Tatiana Yuzyuk, PhD, ABMGG; Evan Raps, MD; Peng Li, MD, PhD; and Valarie McMurtry, MD, PhD.
ARUP’s new test is the first companion diagnostic immunoassay for a gene therapy product to receive FDA approval. FDA has issued simultaneous approval of ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), BioMarin’s gene therapy for severe hemophilia A.
ARUP President and Chief Scientific Officer Tracy I. George, MD, pioneered the central pathology review service that screens and confirms potential patient candidates for clinical trials and monitors their drug responses.
